Article Text

Download PDFPDF
Original research article
Established and novel risk factors for atrial fibrillation in women compared with men
  1. Sanne A E Peters1,
  2. Mark Woodward1,2,3,4
  1. 1 The George Institute for Global Health, University of Oxford, Oxford, UK
  2. 2 Cardiovascular Epidemiology Unit, Institute of Cardiovascular Research, University of Dundee, Dundee, UK
  3. 3 The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
  4. 4 Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA
  1. Correspondence to Dr Sanne A E Peters, The George Institute for Global Health, University of Oxford, Oxford OX1 3QX, UK; sanne.peters{at}georgeinstitute.ox.ac.uk

Footnotes

  • Contributors SAEP and MW conceived and designed the study. SAEP analysed the data and drafted the manuscript. SAEP and MW interpreted the results and contributed to critical revision of the manuscript.

  • Funding The Scottish Heart Health Extended Cohort (SHHEC) was funded by the Scottish Health Department Chief Scientist Organization, the British Heart Foundation and the FP Fleming Trust. The MORGAM collaboration was funded by the European Commission Seventh Framework Programme, references FP7/2007-2013 (HEALTH-F4-2007-2014113, ENGAGE; HEALTH-F3-2010-242244, CHANCES). The MORGAM Biomarker Study (serum biomarkers in the MORGAM populations) was funded by the Medical Research Council, London (reference G0601463, No 80983). The BiomarCaRE Project (Biomarkers for Cardiovascular Risk Assessment in Europe) was funded by the European Commission Seventh Framework Programme FP7/2007-2013 (reference HEALTHF2-2011-278913). SP is supported by a UK Medical Research Council Skills Development Fellowship (MR/P014550/1).

  • Disclaimer Funding bodies had no role in the planning of the study, analyses, interpretation, writing or publication of the manuscript, or recruitment of participants.

  • Competing interests None declared.

  • Patient consent Not required.

  • Ethics approval Ethical approval was received from all relevant medical research ethics committees covering the individual populations involved.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors SAEP and MW conceived and designed the study. SAEP analysed the data and drafted the manuscript. SAEP and MW interpreted the results and contributed to critical revision of the manuscript.

  • Funding The Scottish Heart Health Extended Cohort (SHHEC) was funded by the Scottish Health Department Chief Scientist Organization, the British Heart Foundation and the FP Fleming Trust. The MORGAM collaboration was funded by the European Commission Seventh Framework Programme, references FP7/2007-2013 (HEALTH-F4-2007-2014113, ENGAGE; HEALTH-F3-2010-242244, CHANCES). The MORGAM Biomarker Study (serum biomarkers in the MORGAM populations) was funded by the Medical Research Council, London (reference G0601463, No 80983). The BiomarCaRE Project (Biomarkers for Cardiovascular Risk Assessment in Europe) was funded by the European Commission Seventh Framework Programme FP7/2007-2013 (reference HEALTHF2-2011-278913). SP is supported by a UK Medical Research Council Skills Development Fellowship (MR/P014550/1).

  • Disclaimer Funding bodies had no role in the planning of the study, analyses, interpretation, writing or publication of the manuscript, or recruitment of participants.

  • Competing interests None declared.

  • Patient consent Not required.

  • Ethics approval Ethical approval was received from all relevant medical research ethics committees covering the individual populations involved.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.